

You are invited to a live speaker program

# Treatment Options for Distributive Shock



Join us to learn more about GIAPREZA<sup>®</sup>, a vasoconstrictor approved to increase blood pressure in adults with septic or other distributive shock. During this presentation, we will delve into the efficacy and safety results from the landmark phase 3 ATHOS 3 trial and discuss dosing information.

Presented by:

**CHRISTIAN SANDROCK, MD**

**7/1/2026**

**6:00 PM - 8:30 PM Pacific Time**

Location:

**Crustacean Beverly Hills**

**468 N. Bedford Drive**

**Beverly Hills, CA 90210**

With limited space available, please RSVP to your Innoviva Specialty Therapeutics representative:

**Arvind Bhatnagar**

**(310) 590-5008**

**[arvind.bhatnagar@istx.com](mailto:arvind.bhatnagar@istx.com)**

**We look forward to your participation!**

Please read:

This is a promotional program and no CME credits are offered.

Attendance at this promotional program sponsored by Innoviva Specialty Therapeutics, Inc. is limited to healthcare professionals only. Guests will not be accommodated.

Please note that certain states prohibit or otherwise limit meals and other transfers of value to HCPs, and Innoviva Specialty Therapeutics, Inc. intends to comply with such requirements.

In addition, many employers (eg, hospitals, teaching institutions, the federal government, states, and local governments) place restrictions on what their employees may accept from outside parties as a condition of employment. Innoviva Specialty Therapeutics, Inc. respects these restrictions and asks that you limit your participation to those activities permitted by your employer.

Note that Innoviva Specialty Therapeutics, Inc. is publicly disclosing information regarding the monetary value of meals and related expenses provided to you as an attendee at this program.

## **IMPORTANT SAFETY INFORMATION**

### **Indication**

GIAPREZA (angiotensin II) increases blood pressure in adults with septic or other distributive shock.

### **Contraindications**

None.

### **Warnings and Precautions**

The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in a randomized, double-blind, placebo-controlled study, ATHOS-3. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo-treated patients in the ATHOS-3 study (13% vs. 5%). The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism (VTE) prophylaxis.

*(ISI continued on next page)*

 **GIAPREZA<sup>®</sup>**  
**(angiotensin II)**  
injection for intravenous infusion

## IMPORTANT SAFETY INFORMATION (cont'd)

### Adverse Reactions

The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in  $\geq 4\%$  of patients treated with GIAPREZA and  $\geq 1.5\%$  more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.

### Drug Interactions

Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.

**You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, please contact:**

La Jolla Pharmaceutical Company  
1-800-651-3861  
[medicalinformation@ljpc.com](mailto:medicalinformation@ljpc.com)

U.S. Food and Drug Administration  
1-800-FDA-1088  
[www.fda.gov/medwatch](http://www.fda.gov/medwatch)

For additional information, please see the accompanying [GIAPREZA prescribing information](#).